Literature DB >> 17488817

Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.

Chunxiao Ying1, Ying Li, Chung-Hang Leung, Michael D Robek, Yung-Chi Cheng.   

Abstract

Helioxanthin is a natural product that inhibits the replication of a number of viruses. We found that a previously undescribed helioxanthin analogue, 8-1, exhibited potent anti-hepatitis B virus (HBV) activity with little cytotoxicity. 8-1 suppressed both HBV RNA and protein expression, as well as DNA replication of both wild-type and 3TC-resistant virus. Time-course analyses revealed that RNA expression was blocked first after treatment with 8-1, followed by viral proteins, and then DNA. 8-1 inhibited the activity of all HBV promoters by decreasing the binding of hepatocyte nuclear factor 4 (HNF-4), HNF-3, and fetoprotein factor to the precore/core promoter enhancer II region. The amount of HNF-4 and HNF-3 was decreased posttranscriptionally by 8-1 in HBV-producing cells, but not in HBV-negative cells. Therefore, 8-1 suppresses HBV replication by posttranscriptional down-regulation of critical transcription factors in HBV-producing cells, thus diminishing HBV promoter activity and blocking viral gene expression and replication. This mechanism is unique and different from other anti-HBV compounds previously described.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488817      PMCID: PMC1895983          DOI: 10.1073/pnas.0609883104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  New targets and inhibitors of HBV replication to combat drug resistance.

Authors:  Yung-Chi Cheng; Chun-Xiao Ying; Chung-Hang Leung; Ying Li
Journal:  J Clin Virol       Date:  2005-12       Impact factor: 3.168

2.  Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.

Authors:  G P Hayhurst; Y H Lee; G Lambert; J M Ward; F J Gonzalez
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  The hepatitis B virus core promoter is strongly activated by the liver nuclear receptor fetoprotein transcription factor or by ectopically expressed steroidogenic factor 1.

Authors:  S Gilbert; L Galarneau; A Lamontagne; S Roy; L Bélanger
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures.

Authors:  Valérie Pasquetto; Stefan F Wieland; Susan L Uprichard; Marco Tripodi; Francis V Chisari
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.

Authors:  L Fu; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  Hepatitis B viral core protein activates the hepatitis B viral enhancer II/pregenomic promoter through the nuclear factor kappaB binding site.

Authors:  Jin Ah Kwon; Hyune Mo Rho
Journal:  Biochem Cell Biol       Date:  2002       Impact factor: 3.626

7.  Mechanisms of inhibition of nuclear hormone receptor-dependent hepatitis B virus replication by hepatocyte nuclear factor 3beta.

Authors:  Hong Tang; Alan McLachlan
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids.

Authors:  Karl Deres; Claus H Schröder; Arnold Paessens; Siegfried Goldmann; Hans Jörg Hacker; Olaf Weber; Thomas Krämer; Ulrich Niewöhner; Ulrich Pleiss; Jürgen Stoltefuss; Erwin Graef; Diana Koletzki; Ralf N A Masantschek; Anja Reimann; Rainer Jaeger; Rainer Gross; Bernhard Beckermann; Karl-Heinz Schlemmer; Dieter Haebich; Helga Rübsamen-Waigmann
Journal:  Science       Date:  2003-02-07       Impact factor: 47.728

Review 9.  Regulatory elements of hepatitis B virus transcription.

Authors:  Naazneen Moolla; Michael Kew; Patrick Arbuthnot
Journal:  J Viral Hepat       Date:  2002-09       Impact factor: 3.728

10.  Conditional replication of duck hepatitis B virus in hepatoma cells.

Authors:  Ju-Tao Guo; Melissa Pryce; Xingtai Wang; M Inmaculada Barrasa; Jianming Hu; Christoph Seeger
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more
  19 in total

Review 1.  Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B.

Authors:  Bidisha Mitra; Roshan J Thapa; Haitao Guo; Timothy M Block
Journal:  Antiviral Res       Date:  2018-08-24       Impact factor: 5.970

2.  HBV life cycle and novel drug targets.

Authors:  Daniel Grimm; Robert Thimme; Hubert E Blum
Journal:  Hepatol Int       Date:  2011-03-08       Impact factor: 6.047

3.  Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation.

Authors:  Li Yang; Li-ping Shi; Hai-jun Chen; Xian-kun Tong; Gui-feng Wang; Yang-ming Zhang; Wen-long Wang; Chun-lan Feng; Pei-lan He; Feng-hua Zhu; You-hua Hao; Bao-ju Wang; Dong-liang Yang; Wei Tang; Fa-jun Nan; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2014-02-03       Impact factor: 6.150

4.  Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha.

Authors:  Jun Xu; Weizhen Gu; Chaoyan Li; Xiao Li; Guozhen Xing; Yan Li; Yanhui Song; Wenming Zheng
Journal:  J Nat Med       Date:  2016-03-11       Impact factor: 2.343

5.  Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line.

Authors:  Wei He; Li-Xia Li; Qing-Jiao Liao; Chun-Lan Liu; Xu-Lin Chen
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

6.  Antiviral Activity of Cananga odorata Against Hepatitis B Virus.

Authors:  Puguh Indrasetiawan; Chie Aoki-Utsubo; Muhammad Hanafi; Sri Hartati; Tutik Sri Wahyuni; Masanori Kameoka; Yoshihiko Yano; Hak Hotta; Yoshitake Hayashi
Journal:  Kobe J Med Sci       Date:  2019-11-12

7.  A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation.

Authors:  Ya-Juan Wang; Dong Lu; Yi-Bin Xu; Wei-Qiang Xing; Xian-Kun Tong; Gui-Feng Wang; Chun-Lan Feng; Pei-Lan He; Li Yang; Wei Tang; You-Hong Hu; Jian-Ping Zuo
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

8.  Mucroporin-M1 inhibits hepatitis B virus replication by activating the mitogen-activated protein kinase (MAPK) pathway and down-regulating HNF4α in vitro and in vivo.

Authors:  Zhenhuan Zhao; Wei Hong; Zhengyang Zeng; Yingliang Wu; Kanghong Hu; Xiaohui Tian; Wenxin Li; Zhijian Cao
Journal:  J Biol Chem       Date:  2012-07-12       Impact factor: 5.157

9.  Antiviral treatment of chronic hepatitis B virus (HBV) infections.

Authors:  Erik De Clercq; Geoffrey Férir; Suzanne Kaptein; Johan Neyts
Journal:  Viruses       Date:  2010-05-31       Impact factor: 5.818

Review 10.  Plant-derived lignans as potential antiviral agents: a systematic review.

Authors:  Xin-Ya Xu; Dong-Ying Wang; Yi-Ping Li; Stephen T Deyrup; Hong-Jie Zhang
Journal:  Phytochem Rev       Date:  2021-05-31       Impact factor: 7.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.